Robert L Ferris

List of Publications by Citations

418 papers	24,115 citations	76 h-index	142 g-index
445 ext. papers	29,664 ext. citations	6.3 avg, IF	7.15 L-index

#	Paper	IF	Citations
418	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *New England Journal of Medicine*, **2016**, 375, 1856-1867	59.2	2647
417	Head and neck cancer. *Lancet, The*, **2008**, 371, 1695-709	40	1323
416	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 3390-7	5.6	614
415	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer Discovery*, **2013**, 3, 761-9	24.4	414
414	Lipid accumulation and dendritic cell dysfunction in cancer. *Nature Medicine*, **2010**, 16, 880-6	50.5	386
413	Immunology and Immunotherapy of Head and Neck Cancer. *Journal of Clinical Oncology*, **2015**, 33, 3293-304	24	381
412	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. *Cancer*, **2014**, 120, 3627-34	6.4	379
411	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. *Oral Oncology*, **2018**, 81, 45-51	4.4	372
410	The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. *Immunity*, **2016**, 45, 374-88	32.3	312
409	The mutational landscape of adenoid cystic carcinoma. *Nature Genetics*, **2013**, 45, 791-8	36.3	311
408	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. *Thyroid*, **2015**, 25, 1217-23	6.2	282
407	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. *Journal of Clinical Oncology*, **2017**, 35, 490-497	2.2	273
406	Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. *Journal of Clinical Oncology*, **2010**, 28, 1395-400	2.2	265
405	Interferon-Drives T Fragility to Promote Anti-tumor Immunity. *Cell*, **2017**, 169, 1130-1141.e11	56.2	261
404	Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. *Journal of Clinical Oncology*, **2010**, 28, 4390-9	2.2	243
403	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 1104-1115	21.7	232
402	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) **2019**, 7, 184		223

401	Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. *Clinical Cancer Research*, **2013**, 19, 1858-72	12.9	222
400	Optimal Perioperative Care in Major Head and Neck Cancer Surgery With Free Flap Reconstruction: A Consensus Review and Recommendations From the Enhanced Recovery After Surgery Society. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 292-303	3.9	218
399	First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. *Cancer Discovery*, **2012**, 2, 694-705	24.4	214
398	The changing therapeutic landscape of head and neck cancer. *Nature Reviews Clinical Oncology*, **2019**, 16, 669-683	19.4	195
397	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer. *Cancer Research*, **2016**, 76, 1031-43	10.1	193
396	Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. *Clinical Cancer Research*, **2004**, 10, 3755-62	12.9	192
395	Oncologic Outcomes After Transoral Robotic Surgery: A Multi-institutional Study. *JAMA Otolaryngology - Head and Neck Surgery*, **2015**, 141, 1043-1051	3.9	191
394	Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4233-8	11.5	191
393	American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. *Thyroid*, **2012**, 22, 501-8	6.2	184
392	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. *Cancer*, **2018**, 124, 1682-1690	6.4	180
391	Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. *Head and Neck*, **2007**, 29, 163-88	4.2	180
390	HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. *Clinical Cancer Research*, **2009**, 15, 3740-50	12.9	177
389	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. *Cancer Research*, **2015**, 75, 2200-10	10.1	175
388	Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. *Clinical Cancer Research*, **2006**, 12, 3890-5	12.9	174
387	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. *JAMA Oncology*, **2019**, 5, 204-212	13.4	171
386	American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. *Thyroid*, **2015**, 25, 760-8	6.2	157
385	Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. *OncoImmunology*, **2017**, 6, e1261779	7.2	152
384	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. *Immunity*, **2020**, 52, 183-199.e9	32.3	152

383	Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. *Cancer*, **2013**, 119, 3302-8	6.4	143
382	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. *Cancer Immunology, Immunotherapy*, **2009**, 58, 1853-64	7.4	139
381	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. *Cancer*, **2013**, 119, 3034-42	6.4	138
380	Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. *Clinical Cancer Research*, **2011**, 17, 6174-84	12.9	135
379	Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. *Cancer Research*, **2004**, 64, 1861-6	10.1	134
378	PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. *Cancer Research*, **2015**, 75, 508-518	10.1	133
377	Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. *Journal of Immunology*, **2006**, 176, 3402-9	5.3	127
376	Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. *Cancer Research*, **2005**, 65, 11146-55	10.1	126
375	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	122
374	Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 3285-92	2.2	117
373	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. *Annals of Oncology*, **2020**, 31, 942-950	10.3	117
372	Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. *Immunologic Research*, **2011**, 50, 248-54	4.3	116
371	Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. *Head and Neck*, **2011**, 33, 504-12	4.2	116
370	Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. *Journal of Clinical Oncology*, **2010**, 28, 5294-300	2.2	116
369	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. *Cancer Research*, **2015**, 75, 2200-2210	10.1	114
368	Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. *Journal of Immunology*, **2014**, 193, 1525-30	5.3	111
367	PD-1 Status in CD8 T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. *Cancer Research*, **2017**, 77, 6353-6364	10.1	111
366	Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis. *Oral Oncology*, **2016**, 62, 60-71	4.4	110

365	A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: a role for transoral robotic surgery. *Laryngoscope*, **2013**, 123, 146-51	3.6	110
364	RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E914-22	5.6	110
363	A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. *Cancer*, **2012**, 118, 2069-77	6.4	107
362	Immunotherapy for head and neck cancer: Recent advances and future directions. *Oral Oncology*, **2019**, 99, 104460	4.4	99
361	Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 102-7	4	96
360	Phase I dendritic cell p53 peptide vaccine for head and neck cancer. *Clinical Cancer Research*, **2014**, 20, 2433-44	12.9	95
359	Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. *Head and Neck*, **2010**, 32, 1412-21	4.2	95
358	Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck. *Cancer Research*, **2005**, 65, 2147-56	10.1	94
357	Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. *Cancer Immunology, Immunotherapy*, **2005**, 54, 1072-81	7.4	90
356	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. *Cancer Treatment Reviews*, **2018**, 63, 48-60	14.4	89
355	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. *Journal of Clinical Investigation*, **2018**, 128, 3926-3940	15.9	88
354	Promising systemic immunotherapies in head and neck squamous cell carcinoma. *Oral Oncology*, **2013**, 49, 1089-96	4.4	85
353	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. *Clinical Cancer Research*, **2016**, 22, 5229-5237	12.9	85
352	A 20-Year Review of 75 Cases of Salivary Duct Carcinoma. *JAMA Otolaryngology - Head and Neck Surgery*, **2016**, 142, 489-95	3.9	84
351	Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. *Immunologic Research*, **2005**, 33, 113-33	4.3	84
350	Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2011**, 34, 165-72	2.7	83
349	Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. *Oral Oncology*, **2017**, 67, 146-152	4.4	81
348	A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 480-8	4	81

347	Elective neck dissection and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx. *Laryngoscope*, **2004**, 114, 2228-34	3.6	80
346	Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. *European Journal of Cancer*, **2005**, 41, 807-15	7.5	79
345	Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) **2014**, 2, P69		78
344	Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. *Head and Neck*, **2012**, 34, 1681-703	4.2	77
343	The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2011**, 34, 372-9	2.7	77
342	Immunotherapy for Head and Neck Squamous Cell Carcinoma. *Current Oncology Reports*, **2018**, 20, 22	6.3	75
341	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. *Clinical Cancer Research*, **2019**, 25, 5221-5230	12.9	74
340	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. *Clinical Cancer Research*, **2017**, 23, 707-716	12.9	74
339	Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. *JAMA Otolaryngology*, **2007**, 133, 1277-81		74
338	HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. *Annual Review of Medicine*, **2016**, 67, 91-101	17.4	73
337	PD-L1 Mediates Dysfunction in Activated PD-1 NK Cells in Head and Neck Cancer Patients. *Cancer Immunology Research*, **2018**, 6, 1548-1560	12.5	73
336	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. *Journal of Clinical Oncology*, **2020**, 38, 2476-2487	2.2	72
335	Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. *Cancer Immunology, Immunotherapy*, **2011**, 60, 525-35	7.4	71
334	Combination antiangiogenic therapy and radiation in head and neck cancers. *Oral Oncology*, **2014**, 50, 19-26	4.4	70
333	Analysis of post-transoral robotic-assisted surgery hemorrhage: Frequency, outcomes, and prevention. *Head and Neck*, **2016**, 38 Suppl 1, E776-82	4.2	69
332	Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control. *JAMA Otolaryngology - Head and Neck Surgery*, **2015**, 141, 1104-10	3.9	69
331	Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. *Annals of Surgery*, **2015**, 262, 519-25; discussion 524-5	7.8	69
330	Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 286-93	2.7	68

329	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. *OncoImmunology*, **2019**, 8, 1593805	7.2	66
328	Accuracy of computed tomography in the prediction of extracapsular spread of lymph node metastases in squamous cell carcinoma of the head and neck. *JAMA Otolaryngology - Head and Neck Surgery*, **2013**, 139, 1187-94	3.9	65
327	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 595-605	4	63
326	Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. *Clinical Cancer Research*, **2018**, 24, 4242-4255	12.9	63
325	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. *OncoImmunology*, **2017**, 6, e1329071	7.2	62
324	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. *European Journal of Cancer*, **2017**, 76, 152-166	7.5	62
323	Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. *Journal of the National Cancer Institute*, **2008**, 100, 502-12	9.7	62
322	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. *Oral Oncology*, **2017**, 73, 138-146	4.4	61
321	Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. *Head and Neck*, **2014**, 36, 511-6	4.2	59
320	Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. *Laryngoscope*, **2008**, 118, 2129-34	3.6	59
319	Increased PD-1 and TIM-3 TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. *Cancer Immunology Research*, **2017**, 5, 408-416	12.5	58
318	SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. *Clinical Cancer Research*, **2013**, 19, 798-808	12.9	58
317	Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. *Clinical Cancer Research*, **2005**, 11, 7901-10	12.9	57
316	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. *Immunity*, **2019**, 51, 548-560.e4	32.3	56
315	Transoral robotic surgery alone for oropharyngeal cancer: quality-of-life outcomes. *JAMA Otolaryngology - Head and Neck Surgery*, **2015**, 141, 499-504	3.9	56
314	Community members as recruiters of human subjects: ethical considerations. *American Journal of Bioethics*, **2010**, 10, 3-11	1.1	56
313	Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).. *Journal of Clinical Oncology*, **2020**, 38, 6500-6500	2.2	56
312	Molecular biology of adenoid cystic carcinoma. *Head and Neck*, **2012**, 34, 1665-77	4.2	55

311	TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. *Cancer Immunology, Immunotherapy*, **2013**, 62, 1347-57	7.4	55
310	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. *Cancer Immunology Research*, **2015**, 3, 936-45	12.5	54
309	Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. *Cancer*, **2016**, 122, 3136-3144	6.4	54
308	Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. *Clinical Cancer Research*, **2018**, 24, 4529-4538	12.9	52
307	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 1583-1588	13.4	52
306	Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. *Cancer*, **2017**, 123, 4382-4390	6.4	51
305	Early squamous cell carcinoma of the oral tongue: comparing margins obtained from the glossectomy specimen to margins from the tumor bed. *Oral Oncology*, **2013**, 49, 1077-82	4.4	49
304	Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer. *Clinical Cancer Research*, **2011**, 17, 1858-66	12.9	48
303	Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. *Laryngoscope*, **2010**, 120, 734-8	3.6	48
302	Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality. *Laryngoscope*, **2014**, 124, 1592-7	3.6	47
301	Role of Immunotherapy in Head and Neck Cancer. *Seminars in Radiation Oncology*, **2018**, 28, 12-16	5.5	47
300	HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. *Journal of Clinical Investigation*, **2020**, 130, 1635-1652	15.9	46
299	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. *Head and Neck*, **2016**, 38, 493-8	4.2	46
298	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
297	Epidemiology of head and neck squamous cell cancer among HIV-infected patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 65, 603-10	3.1	45
296	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. *BMC Cancer*, **2013**, 13, 602	4.8	45
295	The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. *Clinical Cancer Research*, **2013**, 19, 889-99	12.9	45
294	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. *Oncologist*, **2018**, 23, 1079-1082	5.7	44

293	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. *Cancer*, **2019**, 125, 3208-3218	6.4	44
292	Lack of toxicity of a STAT3 decoy oligonucleotide. *Cancer Chemotherapy and Pharmacology*, **2009**, 63, 983-95	3.5	44
291	CCR7 mediates inflammation-associated tumor progression. *Immunologic Research*, **2006**, 36, 61-72	4.3	44
290	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce **2020**, 8,		43
289	Diagnosis and management of differentiated thyroid cancer using molecular biology. *Laryngoscope*, **2013**, 123, 1059-64	3.6	42
288	Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. *Oral Oncology*, **2011**, 47, 961-6	4.4	42
287	Chemokine receptor 7 (CCR7) gene expression is regulated by NF-Β and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). *Journal of Biological Chemistry*, **2012**, 287, 3581-90	5.4	42
286	Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. *Laryngoscope*, **2005**, 115, 522-7	3.6	42
285	Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. *Cell Reports*, **2018**, 25, 1332-1345.e5	10.6	42
284	Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions. *Otolaryngology - Head and Neck Surgery*, **2014**, 151, 272-8	5.5	41
283	Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. *Cancer Prevention Research*, **2015**, 8, 197-207	3.2	41
282	Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience. *Head and Neck*, **2020**, 42, 1310-1316	4.2	40
281	Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness Analysis. *Otolaryngology - Head and Neck Surgery*, **2014**, 150, 976-82	5.5	40
280	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. *Clinical Cancer Research*, **2018**, 24, 62-72	12.9	39
279	Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 973-980	4	39
278	Accuracy of computed tomography to predict extracapsular spread in p16-positive squamous cell carcinoma. *Laryngoscope*, **2015**, 125, 1613-8	3.6	39
277	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. *Cancer*, **2014**, 120, 624-32	6.4	39
276	Prospective evaluation of patient-reported quality-of-life outcomes following SBRT □ cetuximab for locally-recurrent, previously-irradiated head and neck cancer. *Radiotherapy and Oncology*, **2012**, 104, 91-5	5.3	39

275	Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. *American Journal of Surgical Pathology*, **2013**, 37, 1586-91	6.7	39
274	TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. *OncoImmunology*, **2013**, 2, e24677	7.2	39
273	Transoral robotic surgery for management of cervical unknown primary squamous cell carcinoma: Updates on efficacy, surgical technique and margin status. *Oral Oncology*, **2017**, 66, 9-13	4.4	38
272	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. *OncoImmunology*, **2018**, 7, e1442168	7.2	38
271	Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx. *Head and Neck*, **2016**, 38 Suppl 1, E2143-50	4.2	38
270	Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. *Carcinogenesis*, **2016**, 37, 522-9	4.6	38
269	Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners. *Head and Neck*, **2015**, 37, 1282-9	4.2	38
268	The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, 483-491	13.4	37
267	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. *Oral Oncology*, **2016**, 58, 52-8	4.4	37
266	National evaluation of multidisciplinary quality metrics for head and neck cancer. *Cancer*, **2017**, 123, 4372-4381	6.4	37
265	Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. *Laryngoscope*, **2014**, 124, 1843-7	3.6	37
264	Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors. *Head and Neck*, **2020**, 42, 1332-1338	4.2	36
263	Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. *Clinical Cancer Research*, **2014**, 20, 3289-98	12.9	36
262	Minimally invasive video-assisted thyroidectomy: expanded indications and oncologic completeness. *Head and Neck*, **2008**, 30, 1403-7	4.2	36
261	Human □defensin 3 promotes NF-B-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck. *Carcinogenesis*, **2011**, 32, 168-74	4.6	35
260	Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. *Proteomics - Clinical Applications*, **2008**, 2, 1575-1585	3.1	35
259	Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery. *Head and Neck*, **2017**, 39, 1510-1515	4.2	35
258	fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 2307-2312	11.5	34

257	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. *Journal of Experimental Medicine*, **2019**, 216, 419-427	16.6	34
256	The central repeat domain 1 of Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) prevents cis MHC class I peptide presentation. *Virology*, **2011**, 412, 357-65	3.6	34
255	Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies. *Head and Neck*, **2011**, 33, 225-231	4.2	34
254	Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. *Radiotherapy and Oncology*, **2010**, 97, 395-8	5.3	34
253	Tumor-infiltrating Tim-3 T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. *OncoImmunology*, **2016**, 5, e1200778	7.2	34
252	Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation. *Radiotherapy and Oncology*, **2013**, 106, 90-5	5.3	33
251	Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. *Journal of Immunotherapy*, **2009**, 32, 465-73	5	33
250	Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. *Laryngoscope*, **2019**, 129, 162-169	3.6	33
249	Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. *Clinical Cancer Research*, **2004**, 10, 6929-37	12.9	32
248	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. *Nature Communications*, **2021**, 12, 3349	17.4	32
247	Risk factors for radiation failure in early-stage glottic carcinoma: A systematic review and meta-analysis. *Oral Oncology*, **2016**, 62, 90-100	4.4	31
246	Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume. *Head and Neck*, **2014**, 36, 1349-55	4.2	31
245	An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. *Laryngoscope*, **1998**, 108, 1686-91	3.6	31
244	Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients **2015**, 3, 54		30
243	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. *Clinical and Experimental Metastasis*, **2012**, 29, 729-36	4.7	30
242	Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. *Head and Neck*, **2012**, 34, 1153-61	4.2	30
241	Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. *Laryngoscope*, **2010**, 120, 71-5	3.6	30
240	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. *JCI Insight*, **2017**, 2, e90449	9.9	30

239	Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. *Journal of Immunotherapy*, **2010**, 33, 83-91	5	29
238	AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. *Head and Neck*, **2018**, 40, 1881-1888	4.2	29
237	Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. *Frontiers in Oncology*, **2019**, 9, 464	5.3	28
236	Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer. *Frontiers in Oncology*, **2014**, 4, 214	5.3	28
235	Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. *Journal of Surgical Oncology*, **2011**, 103, 518-30	2.8	28
234	Characterization of human papillomavirus antibodies in individuals with head and neck cancer. *Cancer Epidemiology*, **2016**, 42, 46-52	2.8	28
233	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. *Head and Neck*, **2017**, 39, 840-852	4.2	27
232	Transoral tongue base mucosectomy for the identification of the primary site in the work-up of cancers of unknown origin: Systematic review and meta-analysis. *Oral Oncology*, **2019**, 91, 97-106	4.4	27
231	Overview of Advances in Head and Neck Cancer. *Journal of Clinical Oncology*, **2015**, 33, 3225-6	2.2	27
230	EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. *OncoImmunology*, **2013**, 2, e27215	7.2	27
229	Defective NF-Β signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. *Cancer Research*, **2012**, 72, 45-55	10.1	27
228	Further evaluations of nivolumab (nivo) versus investigator□s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. *Journal of Clinical Oncology*, **2016**, 34, 6009-6009	2.2	27
227	Perineural Invasion in Parotid Gland Malignancies. *Otolaryngology - Head and Neck Surgery*, **2018**, 158, 1035-1041	5.5	26
226	MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. *BMC Cancer*, **2015**, 15, 861	4.8	26
225	Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. *Head and Neck*, **2011**, 33, 318-23	4.2	26
224	Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. *International Journal of Cancer*, **2009**, 125, 1912-20	7.5	26
223	A prospective evaluation of short-term dysphagia after transoral robotic surgery for squamous cell carcinoma of the oropharynx. *Cancer*, **2017**, 123, 3132-3140	6.4	25
222	STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV status in head and neck cancer. *Oral Oncology*, **2018**, 78, 186-193	4.4	25

221	Rapid molecular detection of metastatic head and neck squamous cell carcinoma as an intraoperative adjunct to sentinel lymph node biopsy. *Laryngoscope*, **2012**, 122, 1020-30	3.6	25
220	Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. *Clinical Immunology*, **2005**, 116, 27-36	9	25
219	Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?. *Orl*, **2004**, 66, 332-40	2	25
218	Utility of up-front transoral robotic surgery in tailoring adjuvant therapy. *Head and Neck*, **2016**, 38, 1201-7	4.2	25
217	Tailored immunotherapy for HPV positive head and neck squamous cell cancer. *Oral Oncology*, **2014**, 50, 780-4	4.4	24
216	Oncologic and functional outcomes of partial laryngeal surgery for intermediate-stage laryngeal cancer. *Otolaryngology - Head and Neck Surgery*, **2013**, 148, 235-42	5.5	24
215	The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. *JAMA Otolaryngology*, **2011**, 137, 1106-11		24
214	Reoperative parathyroidectomy. *Otolaryngologic Clinics of North America*, **2008**, 41, 1269-74, xii	2	24
213	Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 542-548	3.9	23
212	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. *Oral Oncology*, **2020**, 108, 104736	4.4	23
211	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. *Oral Oncology*, **2019**, 96, 7-14	4.4	23
210	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial **2021**, 9,		23
209	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. *Oncologist*, **2017**, 22, 680-693	5.7	22
208	Utility of a perioperative nutritional intervention on postoperative outcomes in high-risk head & neck cancer patients. *Oral Oncology*, **2016**, 54, 42-6	4.4	22
207	Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. *PLoS ONE*, **2014**, 9, e102452	3.7	22
206	NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. *Clinical Cancer Research*, **2007**, 13, 5663-4	12.9	22
205	Diagnostic assessment of laryngeal cancer. *Otolaryngologic Clinics of North America*, **2002**, 35, 953-69, v	2	22
204	Association of Lymphovascular Space Invasion With Locoregional Failure and Survival in Patients With Node-Negative Oral Tongue Cancers. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 382-388	3.9	21

203	Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. *Cancer Immunology Research*, **2016**, 4, 441-51	12.5	21
202	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. *Oral Oncology*, **2019**, 96, 140-147	4.4	21
201	Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. *Frontiers in Pharmacology*, **2017**, 8, 382	5.6	21
200	Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. *Clinical Cancer Research*, **2006**, 12, 2394-403	12.9	21
199	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. *Journal of Clinical Oncology*, **2014**, 32, LBA6006-LBA6006	2.2	21
198	A systematic review and meta-analysis of margins in transoral surgery for oropharyngeal carcinoma. *Oral Oncology*, **2019**, 98, 69-77	4.4	20
197	Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. *Cancer*, **2016**, 122, 2021-30	6.4	20
196	Multi-institutional investigation of the prognostic value of lymph nodel yield in advanced-stage oral cavity squamous cell carcinoma. *Head and Neck*, **2014**, 36, 1446-52	4.2	20
195	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). *Journal of Clinical Oncology*, **2021**, JCO2101752	2.2	20
194	Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma. *Head and Neck*, **2016**, 38, 1467-71	4.2	20
193	Is There a Role for Robotic Surgery in the Treatment of Head and Neck Cancer?. *Current Treatment Options in Oncology*, **2016**, 17, 29	5.4	20
192	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. *Head and Neck*, **2018**, 40, 1685-1690	4.2	20
191	Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 806-812	4	19
190	Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base. *Cancer*, **2019**, 125, 2782-2793	6.4	19
189	Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 195-200	4	19
188	Posttreatment quality-of-life assessment in patients with head and neck cancer treated with intensity-modulated radiation therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2011**, 34, 478-82	2.7	19
187	Current concepts and new horizons in conservation laryngeal surgery: an important part of multidisciplinary care. *Head and Neck*, **2010**, 32, 656-65	4.2	19
186	PET-CT staging of the neck in cancers of the oropharynx: patterns of regional and retropharyngeal nodal metastasis. *World Journal of Surgical Oncology*, **2010**, 8, 70	3.4	19

185	T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. *OncoImmunology*, **2018**, 7, e1494112	7.2	19
184	Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history. *Oral Oncology*, **2014**, 50, 1104-8	4.4	18
183	Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors. *Oral Oncology*, **2013**, 49, 401-6	4.4	18
182	Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. *Frontiers in Pharmacology*, **2017**, 8, 332	5.6	18
181	A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer. *Head & Neck Oncology*, **2012**, 4, 12		18
180	Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. *European Archives of Oto-Rhino-Laryngology*, **2006**, 263, 313-8	3.5	18
179	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. *International Journal of Radiation Biology*, **2021**, 97, 1121-1128	2.9	17
178	Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. *Head and Neck*, **2013**, 35, 1499-506	4.2	17
177	Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. *Current Oncology Reports*, **2009**, 11, 156-62	6.3	17
176	Diagnostic utility of positron emission tomography-computed tomography for predicting malignancy in cystic neck masses in adults. *Laryngoscope*, **2005**, 115, 1979-82	3.6	17
175	Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment. *Oral Oncology*, **2018**, 87, 170-176	4.4	17
174	Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage. *Cancer*, **2019**, 125, 3198-3207	6.4	16
173	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. *Future Oncology*, **2020**, 16, 1235-1243	3.6	16
172	Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. *Journal of Immunology*, **2016**, 196, 2870-8	5.3	16
171	Adjuvant stereotactic body radiotherapy□cetuximab following salvage surgery in previously irradiated head and neck cancer. *Laryngoscope*, **2014**, 124, 1579-84	3.6	16
170	The role of cetuximab in the management of head and neck cancers. *Expert Opinion on Biological Therapy*, **2012**, 12, 517-28	5.4	16
169	Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck **2021**, 9,		16
168	Hemorrhagic and Cystic Brain Metastases Are Associated With an Increased Risk of Leptomeningeal Dissemination After Surgical Resection and Adjuvant Stereotactic Radiosurgery. *Neurosurgery*, **2019**, 85, 632-641	3.2	16

167	EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. *PLoS ONE*, **2018**, 13, e0203402	3.7	16
166	Minimizing adjuvant treatment after transoral robotic surgery through surgical margin revision and exclusion of radiographic extracapsular extension: A Prospective observational cohort study. *Head and Neck*, **2017**, 39, 965-973	4.2	15
165	Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma. *Oral Oncology*, **2016**, 60, 55-60	4.4	15
164	Head and neck cancer immunotherapy: clinical evaluation. *Current Oncology Reports*, **2008**, 10, 162-9	6.3	15
163	E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).. *Journal of Clinical Oncology*, **2013**, 31, 6005-6005	2.2	15
162	Current Role of Surgery in the Management of Oropharyngeal Cancer. *Journal of Oncology Practice*, **2016**, 12, 1176-1183	3.1	15
161	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. *Journal of Virology*, **2019**, 93,	6.6	15
160	Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma. *Otolaryngology - Head and Neck Surgery*, **2018**, 158, 660-666	5.5	15
159	Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. *Cell Reports*, **2018**, 25, 2208-2222.e7	10.6	15
158	Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically. *Oral Oncology*, **2017**, 65, 89-93	4.4	14
157	Solid Lymph Nodes as an Imaging Biomarker for Risk Stratification in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. *American Journal of Neuroradiology*, **2017**, 38, 1405-1410	4.4	14
156	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. *Molecular Cancer Research*, **2017**, 15, 179-188	6.6	14
155	Sparing Cardiac Substructures With Optimized Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-small Cell Lung Cancer. *Practical Radiation Oncology*, **2019**, 9, e473-e481	2.8	14
154	Major head and neck reconstruction during the COVID-19 pandemic: The University of Pittsburgh approach. *Head and Neck*, **2020**, 42, 1243-1247	4.2	14
153	STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells. *Molecular Cancer Therapeutics*, **2015**, 14, 2103-11	6.1	13
152	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). *Head and Neck*, **2020**, 42, 2852-2862	4.2	13
151	Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy. *Radiotherapy and Oncology*, **2018**, 126, 100-106	5.3	13
150	Factors Influencing the Incidence of Severe Complications in Head and Neck Free Flap Reconstructions. *Plastic and Reconstructive Surgery - Global Open*, **2016**, 4, e1013	1.2	13

149	Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort. *Oral Oncology*, **2018**, 84, 82-87	4.4	13
148	Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. *Seminars in Oncology*, **2014**, 41, 678-84	5.5	13
147	Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. *Oral Oncology*, **2017**, 75, 184-188	4.4	13
146	Correlation of tumor marker expression with nodal disease burden in metastatic head and neck cancer. *Otolaryngology - Head and Neck Surgery*, **2013**, 149, 261-8	5.5	13
145	Functional laryngeal dyskinesia in children and adults. *Laryngoscope*, **1998**, 108, 1520-3	3.6	13
144	A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. *Oral Oncology*, **2020**, 110, 104797	4.4	13
143	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. *Cancers of the Head & Neck*, **2016**, 1, 12	5.9	13
142	Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. *Current Treatment Options in Oncology*, **2018**, 19, 68	5.4	13
141	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. *Head and Neck*, **2019**, 41, 2591-2601	4.2	12
140	Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer. *International Journal of Cancer*, **2018**, 142, 2518-2528	7.5	12
139	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. *Cancer*, **2018**, 124, 84-94	6.4	12
138	Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. *Head and Neck*, **2016**, 38 Suppl 1, E1613-7	4.2	12
137	Prevention and management of dysphonia during anterior cervical spine surgery. *Laryngoscope*, **2012**, 122, 2179-83	3.6	12
136	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. *Head and Neck*, **2020**, 42, 3141-3152	4.2	12
135	Oncogenic growth factor signaling mediating tumor escape from cellular immunity. *Current Opinion in Immunology*, **2017**, 45, 52-59	7.8	11
134	Defining the Prevalence and Prognostic Value of Perineural Invasion and Angiolymphatic Invasion in Human Papillomavirus-Positive Oropharyngeal Carcinoma. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 1236-1243	3.9	11
133	Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. *Head and Neck*, **2019**, 41, 3056-3063	4.2	11
132	Accuracy of early-phase versus dual-phase single-photon emission computed tomography/computed tomography in the localization of parathyroid disease. *Laryngoscope*, **2015**, 125, 1496-501	3.6	11

131	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. *Oral Oncology*, **2019**, 95, 106-114	4.4	11
130	Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules. *Otolaryngologic Clinics of North America*, **2014**, 47, 557-71	2	11
129	Acute neurorehabilitation: does a neurosensory and coordinated interdisciplinary programme reduce tracheostomy weaning time and weaning failure?. *NeuroRehabilitation*, **2014**, 34, 809-17	2	11
128	Large-scale analysis of B-cell epitopes on influenza virus hemagglutinin - implications for cross-reactivity of neutralizing antibodies. *Frontiers in Immunology*, **2014**, 5, 38	8.4	11
127	Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. *Oral Oncology*, **2012**, 48, 1136-45	4.4	11
126	EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. *Journal of Translational Medicine*, **2011**, 9, 168	8.5	11
125	Molecular biology of primary hyperparathyroidism. *Otolaryngologic Clinics of North America*, **2004**, 37, 819-31, x	2	11
124	Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers. *Oral Oncology*, **2020**, 100, 104475	4.4	11
123	Cancer of the oropharynx. *Surgical Oncology Clinics of North America*, **2015**, 24, 509-20	2.7	10
122	Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. *Cancers*, **2020**, 12,	6.6	10
121	Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. *Head and Neck*, **2016**, 38 Suppl 1, E494-501	4.2	10
120	CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. *Cancer Immunology, Immunotherapy*, **2010**, 59, 1561-8	7.4	10
119	Exploring websites on cancer clinical trials: an empirical review. *Contemporary Clinical Trials*, **2005**, 26, 530-3	2.3	10
118	Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. *Journal of Clinical Oncology*, **2020**, 38, 3983-3986	2.2	10
117	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. *Science Immunology*, **2020**, 5,	28	10
116	Hypopharyngeal cancer treatment: Does initial surgery confer survival benefit?. *Head and Neck*, **2019**, 41, 2167-2173	4.2	10
115	TORS Base-of-Tongue Mucosectomy in Human Papilloma Virus-Negative Carcinoma of Unknown Primary. *Laryngoscope*, **2021**, 131, 78-81	3.6	10
114	Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study. *European Journal of Cancer*, **2018**, 103, 69-77	7.5	10

113	Thyroidectomy in patients who have undergone gastric bypass surgery. *Head and Neck*, **2018**, 40, 1237-1244	4.4	9
112	Postoperative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities. *Practical Radiation Oncology*, **2017**, 7, e419-e425	2.8	9
111	Surgical trials in head and neck oncology: Renaissance and revolution?. *Head and Neck*, **2015**, 37, 927-30	4.2	9
110	Sentinel lymph node biopsy versus selective neck dissection for detection of metastatic oral squamous cell carcinoma. *Clinical and Experimental Metastasis*, **2012**, 29, 693-8	4.7	9
109	Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).. *Journal of Clinical Oncology*, **2021**, 39, 6010-6010	2.2	9
108	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. *Science Advances*, **2021**, 7,	14.3	9
107	Staged Reconstruction (Delayed-Immediate) of the Maxillectomy Defect Using CAD/CAM Technology. *Journal of Reconstructive Microsurgery*, **2018**, 34, 193-199	2.5	9
106	Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells. *Oral Oncology*, **2013**, 49, 591-7	4.4	8
105	Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. *Oral Oncology*, **2014**, 50, 662-9	4.4	8
104	Steroid psychosis after head and neck surgery: case report and review of the literature. *Otolaryngology - Head and Neck Surgery*, **2003**, 129, 591-2	5.5	8
103	Utility of Diagnostic Molecular Markers for Evaluation of Indeterminate Thyroid Nodules. *JAMA Otolaryngology - Head and Neck Surgery*, **2016**, 142, 421-2	3.9	7
102	Immunotherapy for head and neck cancer. *Oral Oncology*, **2009**, 45, 747-51	4.4	7
101	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.. *Nature Communications*, **2021**, 12, 7338	17.4	7
100	Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. *Oral Oncology*, **2016**, 53, 60-6	4.4	7
99	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. *Head and Neck*, **2019**, 41, 843-856	4.2	7
98	Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity. *Frontiers in Oncology*, **2020**, 10, 688	5.3	6
97	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. *Oral Oncology*, **2018**, 77, 92-97	4.4	6
96	Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer. *Scientific Reports*, **2018**, 8, 10716	4.9	6

95	Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response. *Cancers*, **2019**, 11,	6.6	6
94	Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy. *Frontiers in Oncology*, **2015**, 5, 65	5.3	6
93	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. *Journal of Clinical Oncology*, **2014**, 32, LBA6006-LBA6006	2.2	6
92	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. *Cancer*, **2020**, 126, 37-45	6.4	6
91	The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma. *Journal of Pathology*, **2020**, 250, 107-119	9.4	6
90	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee **2020**, 8,		6
89	CD40 Agonist Targeted to Fibroblast Activation Protein Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. *Clinical Cancer Research*, **2021**, 27, 4054-4065	12.9	6
88	Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers. *Radiotherapy and Oncology*, **2019**, 131, 192-201	5.3	6
87	Reproducibility in contouring the neurovascular bundle for prostate cancer radiation therapy. *Practical Radiation Oncology*, **2018**, 8, e125-e131	2.8	6
86	Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III. *Head and Neck*, **2019**, 41, 1178-1183	4.2	5
85	Proposal of a timing strategy for cholesteatoma surgery during the COVID-19 pandemic. *European Archives of Oto-Rhino-Laryngology*, **2020**, 277, 2619-2623	3.5	5
84	PD-1 immunotherapy for recurrent or metastatic HNSCC. *Lancet, The*, **2019**, 394, 1882-1884	40	5
83	Use of combined suspension laryngoscopy and jet ventilation for Y-shaped airway stents delivery. *Annals of Thoracic Surgery*, **2014**, 97, 2208-10	2.7	5
82	Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).. *Journal of Clinical Oncology*, **2014**, 32, 6033-6033	2.2	5
81	The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors. *Head and Neck*, **2021**, 43, 3062-3075	4.2	5
80	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. *Head and Neck*, **2017**, 39, 2433-2443	4.2	4
79	Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. *Journal of Clinical Oncology*, **2019**, 37, 1683-1685	2.2	4
78	Congenital lobar emphysema presenting as an airway foreign body. *International Journal of Pediatric Otorhinolaryngology*, **2015**, 79, 2450-2	1.7	4

77	Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. *Head and Neck*, **2018**, 40, 1743-1751	4.2	4
76	Management of Pharyngeal Fistulas After Anterior Cervical Spine Surgery: A Treatment Algorithm for Severe Complications. *Clinical Spine Surgery*, **2017**, 30, E25-E30	1.8	4
75	Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).. *Journal of Clinical Oncology*, **2014**, 32, 6090-6090	2.2	4
74	Reconstruction of TORS oropharyngectomy defects with the nasoseptal flap via transpalatal tunnel. *Journal of Robotic Surgery*, **2020**, 14, 311-316	2.9	4
73	The addition of chemotherapy in the definitive management of high risk prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 475-487	2.8	4
72	Transoral robotic-assisted supracricoid partial laryngectomy with cricohyoidoepiglottopexy: Procedure development and outcomes of initial cases. *Head and Neck*, **2018**, 40, 2254-2262	4.2	4
71	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. *Scientific Reports*, **2020** , 10, 8031	4.9	3
70	Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer. *Frontiers in Oncology*, **2020**, 10, 83	5.3	3
69	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines23-43		3
68	Head and neck squamous and thyroid carcinomas: multiplexed Luminex approaches for early detection. *Expert Opinion on Medical Diagnostics*, **2007**, 1, 129-36		3
67	Bleeding complications in patients with squamous cell carcinoma of the head and neck. *Head and Neck*, **2021**, 43, 2844-2858	4.2	3
66	Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model. *OncoImmunology*, **2021**, 10, 1912473	7.2	3
65	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. *Cancer*, **2021**, 127, 1779-1787	6.4	3
64	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. *Cell Reports*, **2021**, 36, 109699	10.6	3
63	Best Practice in Surgical Treatment of Malignant Head and Neck Tumors. *Frontiers in Oncology*, **2020**, 10, 140	5.3	2
62	Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. *American Journal of Medicine* , **2016**, 129, e29-31	2.4	2
61	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. *Cancer*, **2018**, 124, 3586-3595	6.4	2
60	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). *Frontiers in Oncology*, **2019**, 9, 1125	5.3	2

59	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology). *Frontiers in Oncology*, **2019**, 9, 1126	5.3	2
58	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers). *Frontiers in Oncology*, **2019**, 9, 1128	5.3	2
57	Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind. *JAMA Oncology*, **2015**, 1, 915-7	13.4	2
56	Response to open peer commentaries on "Community members as recruiters of human subjects: ethical considerations". *American Journal of Bioethics*, **2010**, 10, W1-3	1.1	2
55	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. *Nature Communications*, **2021**, 12, 6340	17.4	2
54	Dose-response modeling the risk of carotid bleeding events after stereotactic body radiation therapy for previously irradiated head and neck cancer. *Journal of Radiosurgery and SBRT*, **2019**, 6, 83-89	0.4	2
53	Dose-response model for severe late laryngeal toxicity after stereotactic body radiation therapy for previously-irradiated head and neck cancer. *Journal of Radiosurgery and SBRT*, **2020**, 7, 89-94	0.4	2
52	HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures. *Carcinogenesis*, **2021**, 42, 14-20	4.6	2
51	Systemic immune dysfunction in cancer patients driven by IL6 and IL8 induction of an inhibitory receptor module in peripheral CD8+ T cells		2
50	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. *Cancers*, **2021**, 13,	6.6	2
49	Transthyrohyoid access to the larynx for endoscopic resection of early-stage glottic cancer. *Head and Neck*, **2016**, 38, 1286-9	4.2	2
48	PET/CT Poorly Predicts AJCC 8th Edition Pathologic Staging in HPV-Related Oropharyngeal Cancer. *Laryngoscope*, **2021**, 131, 1535-1541	3.6	2
47	Characterizing postoperative physiologic swallow function following transoral robotic surgery for early stage tonsil, base of tongue, and unknown primary human papillomavirus-associated squamous cell carcinoma. *Head and Neck*, **2021**, 43, 1629-1640	4.2	2
46	Epidermal Growth Factor Receptor-Targeted Therapy for Head and Neck Cancer. *Otolaryngologic Clinics of North America*, **2021**, 54, 743-749	2	2
45	APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma. *Viruses*, **2021**, 13,	6.2	2
44	Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?. *Journal of Clinical Oncology*, **2021**, 39, 2732-2733	2.2	2
43	Response to Letter to the Editor regarding follow-up for NIFTP. *Head and Neck*, **2019**, 41, 835	4.2	1
42	A new endoscopic surgical approach to the larynx, hypopharynx, and neck lymphatics: The robotic-assisted extended "Sistrunk" approach (RESA). *Head and Neck*, **2020**, 42, 2750-2756	4.2	1

41	Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma. *Journal of Radiation Oncology*, **2018**, 7, 187-193	0.7	1
40	Response to Letter to the Editor on COI for American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules. *Thyroid*, **2015**, 25, 1266	6.2	1
39	In regard to "ACR appropriateness criteria of recurrent head-and-neck cancer after prior definitive radiation." (Int J Radiat Oncol Biol Phys 2011;80:1292-1298). *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1322-3; author reply 1315-6	4	1
38	Expression of Tim-3 drives naïve Treg to an effector-like state with enhanced suppressive activity		1
37	Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures		1
36	Immunology of Head and Neck Cancer **2011**, 107-119		1
35	Perceived Financial Insecurity Impacts Healthcare Decision-Making Among Patients With Sinusitis. *Laryngoscope*, **2021**, 131, 2403-2412	3.6	1
34	Reply to N. Hirshoren et al and D. Chakrabarti et al. *Journal of Clinical Oncology*, **2021**, 39, 1600-1601	2.2	1
33	Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: Results from an EORTC led survey. *Journal of Geriatric Oncology*, **2021**, 12, 1261-1265	3.6	1
32	Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis. *Cancer*, **2021**, 127, 1993-2002	6.4	1
31	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC) **2018**, 341-355		1
30	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.. *JID Innovations*, **2021**, 1, 100045		1
29	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. *Science Translational Medicine*, **2021**, 13, eabf8495	17.5	1
28	Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adults.. *Tumour Virus Research*, **2022**, 200237		1
27	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. *Cancers*, **2022**, 14, 2639	6.6	1
26	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.. *Frontiers in Oncology*, **2022**, 12, 730785	5.3	0
25	Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).. *Journal of Clinical Oncology*, **2014**, 32, TPS6104-TPS6104	2.2	0
24	Immunotherapeutic approaches in HNSCC **2020**, 117-142		0

23	Surgical factors associated with patient-reported quality of life outcomes after free flap reconstruction of the oral cavity. *Oral Oncology*, **2021**, 123, 105574	4.4	0
22	Otogenic Pneumocephalus Presenting as Pneumatocele of the Scalp. *American Journal of Medicine*, **2019**, 132, 1170-1172	2.4	
21	Immune Escape and Immunotherapy of HPV-Related Oropharyngeal Cancer: Has the Future Arrived?. *Current Otorhinolaryngology Reports*, **2015**, 3, 63-72	0.5	
20	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). *Frontiers in Oncology*, **2019**, 9, 1127	5.3	
19	Re-irradiation strategies for head-and-neck cancers: implications for stereotactic body radiotherapy: in regard to Chen et al (Int J Radiant Oncol Biol Phys 2011;81:1211-1219). *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 769-70	4	
18	Response to the letter to the editors by Ottaiano et al.: Cetuximab-dependent ADCC in cancer: dream or reality? *Cancer Immunology, Immunotherapy*, **2010**, 59, 1609-1610	7.4	
17	Quality of life and health-related utility after trans-oral surgery for head and neck cancers. *Health and Quality of Life Outcomes*, **2021**, 19, 250	3	
16	STAT3 and immune escape in head and neck squamous cell carcinoma. *FASEB Journal*, **2008**, 22, 1078.23	0.9	
15	Autocrine CCR7 signaling is mediated by NF-kappaB in SCCHN. *FASEB Journal*, **2008**, 22, 1070.32	0.9	
14	CD8+ T cell Recognition of Polymorphic Wild Type Sequence p53657̈3 Peptides in Squamous Cell Carcinoma of the Head and Neck. *FASEB Journal*, **2008**, 22, 1079.15	0.9	
13	Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. *FASEB Journal*, **2008**, 22, 1068.22	0.9	
12	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). *Current Cancer Research*, **2018**, 365-396	0.2	
11	Use of Intraoperative Indocyanine Green Endoscopy in the Assessment of Vascularity of Intranasal Flaps. *Journal of Neurological Surgery, Part B: Skull Base*, **2018**, 79, S1-S188	1.5	
10	Endonasal Suturing of Nasoseptal Flap to the Nasopharyngeal Fascia Using the V-Loc Wound Closing Device. *Journal of Neurological Surgery, Part B: Skull Base*, **2018**, 79, S1-S188	1.5	
9	Perineural Spread of Squamous Cell Carcinoma to the Skull Base following Treatment of Oropharyngeal P16-Positive Squamous Cell Carcinoma: A Case Series. *Journal of Neurological Surgery, Part B: Skull Base*, **2018**, 79, S1-S188	1.5	
8	Improving responses to immunotherapy in head and neck squamous cell carcinoma **2020**, 107-133		
7	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. *Journal of Clinical Oncology*, **2014**, 32, 6086-6086	2.2	
6	Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).. *Journal of Clinical Oncology*, **2014**, 32, TPS3123-TPS3123	2.2	

5	Evaluation of computational tools to determine prognostic significance of TP53 mutation in head and neck squamous cell carcinoma (HNSCC).. *Journal of Clinical Oncology*, **2014**, 32, 6035-6035	2.2
4	Evaluation of Intranasal Flap Perfusion by Intraoperative ICG Fluorescence Angiography. *Journal of Neurological Surgery, Part B: Skull Base*, **2017**, 78, S1-S156	1.5
3	Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic. *Frontiers in Oncology*, **2021**, 11, 651123	5.3
2	Immunology of Head and Neck Cancer **2016**, 133-148	
1	Reply to A.S. Garden.. *Journal of Clinical Oncology*, **2022**, JCO2200063	2.2